{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T15:21:41Z","timestamp":1767626501848,"version":"3.40.5"},"reference-count":139,"publisher":"Informa UK Limited","issue":"33","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.2217\/fon-2021-0318","type":"journal-article","created":{"date-parts":[[2021,8,25]],"date-time":"2021-08-25T11:21:57Z","timestamp":1629890517000},"page":"4583-4606","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":5,"title":["Systemic and Liver-Directed Therapies in Metastatic Uveal Melanoma: State-of-the-Art and Novel Perspectives"],"prefix":"10.1080","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8591-0788","authenticated-orcid":false,"given":"Francesca","family":"Comito","sequence":"first","affiliation":[{"name":"Division of Oncology,IRCCS Azienda Ospedaliero-Universitaria di Bologna"},{"name":"Department of Experimental,Diagnostic &amp; Specialty Medicine,S. Orsola-Malpighi University Hospital of Bologna 40138,\rItaly"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola Valeria","family":"Marchese","sequence":"additional","affiliation":[{"name":"Department of Experimental,Diagnostic &amp; Specialty Medicine,S. Orsola-Malpighi University Hospital of Bologna 40138,\rItaly"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela Dalia","family":"Ricci","sequence":"additional","affiliation":[{"name":"Department of Experimental,Diagnostic &amp; Specialty Medicine,S. Orsola-Malpighi University Hospital of Bologna 40138,\rItaly"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nastassja","family":"Tober","sequence":"additional","affiliation":[{"name":"Department of Experimental,Diagnostic &amp; Specialty Medicine,S. Orsola-Malpighi University Hospital of Bologna 40138,\rItaly"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Peterle","sequence":"additional","affiliation":[{"name":"Department of Experimental,Diagnostic &amp; Specialty Medicine,S. Orsola-Malpighi University Hospital of Bologna 40138,\rItaly"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Sperandi","sequence":"additional","affiliation":[{"name":"Division of Oncology,IRCCS Azienda Ospedaliero-Universitaria di Bologna"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Melotti","sequence":"additional","affiliation":[{"name":"Division of Oncology,IRCCS Azienda Ospedaliero-Universitaria di Bologna"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2021,8,25]]},"reference":[{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19981015)83:8<1664::AID-CNCR23>3.0.CO;2-G"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaapos.2011.10.012"},{"issue":"18","key":"e_1_3_2_5_1","first-page":"5712","article-title":"Lack of BRAF mutations in uveal melanoma","volume":"63","author":"Rimoldi Donata","year":"2003","unstructured":"Rimoldi Donata , SalviSuzanne, Li\u00e9nardDanielleet al. Lack of BRAF mutations in uveal melanoma. Cancer Res.63 (18), 5712\u20135715 (2003).","journal-title":"Cancer Res."},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.804"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2013.418"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2014.05.028"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1210407"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2016.09.008"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2017.07.003"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.03-0538"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-3768.1982.tb08371.x"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/00008390-200112000-00006"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-200306000-00002"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/00008390-200510000-00014"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl309"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-004-0569-4"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602586"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/00008390-200506000-00010"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.cmr.0000205017.38859.07"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000401"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/00008390-200306000-00013"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10996"},{"issue":"2","key":"e_1_3_2_25_1","first-page":"201","article-title":"BOLD + interferon in the treatment of metastatic uveal melanoma: first report of active systemic therapy","volume":"16","author":"Nathan FE","year":"1997","unstructured":"Nathan FE , BerdD, SatoTet al. BOLD + interferon in the treatment of metastatic uveal melanoma: first report of active systemic therapy. J. Exp. Clin. Cancer Res.16(2), 201\u2013208 (1997).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(03)00132-1"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0b013e328311aaa1"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0b013e3283403ce9"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-200202000-00009"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12082270"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/00008390-200412000-00001"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2014.261"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70269-3"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.6096"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.1090"},{"issue":"15","key":"e_1_3_2_36_1","article-title":"Multi-center phase Ib study of intermittent dosing of the MEK inhibitor, selumetinib, in patients with advanced uveal melanoma not previously treated with a MEK inhibitor","volume":"35","author":"Komatsubara KM","year":"2017","unstructured":"Komatsubara KM , ShoushtariAN, PatelSPet al. Multi-center phase Ib study of intermittent dosing of the MEK inhibitor, selumetinib, in patients with advanced uveal melanoma not previously treated with a MEK inhibitor. J. Clin. Oncol.35(Suppl. 15), (2017).","journal-title":"J. Clin. Oncol."},{"issue":"15","key":"e_1_3_2_37_1","article-title":"Phase I dose-escalation study of the protein kinase C (PKC) inhibitor AEB071 in patients with metastatic uveal melanoma","volume":"32","author":"Piperno-Neumann S","year":"2014","unstructured":"Piperno-Neumann S , KapiteijnE, LarkinJMGet al. Phase I dose-escalation study of the protein kinase C (PKC) inhibitor AEB071 in patients with metastatic uveal melanoma. J. Clin. Oncol.32(Suppl. 15), (2014).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_2_38_1","volume-title":"Clinical Trials.","author":"Kapiteijn E","year":"2019","unstructured":"Kapiteijn E , CarlinoM, BoniVet al. Abstract CT068: a phase I trial of LXS196, a novel PKC inhibitor for metastatic uveal melanoma. In: Clinical Trials.American Association for Cancer Research (2019)."},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-12-1020"},{"issue":"15","key":"e_1_3_2_40_1","article-title":"A randomized phase 2 study of trametinib with or without GSK2141795 in patients with advanced uveal melanoma","volume":"34","author":"Shoushtari AN","year":"2016","unstructured":"Shoushtari AN , KudchadkarRR, PanageasKet al. A randomized phase 2 study of trametinib with or without GSK2141795 in patients with advanced uveal melanoma. J. Clin. Oncol.34(Suppl. 15), (2016).","journal-title":"J. Clin. Oncol."},{"issue":"15","key":"e_1_3_2_41_1","article-title":"A phase II study of ERK inhibition by ulixertinib (BVD-523) in metastatic uveal melanoma","volume":"38","author":"Buchbinder EI","year":"2020","unstructured":"Buchbinder EI , CohenJV, HaqRet al. A phase II study of ERK inhibition by ulixertinib (BVD-523) in metastatic uveal melanoma. J. Clin. Oncol.38(Suppl. 15), (2020).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1080\/02713680600865052"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2015-0501"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-1463"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0048787"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2016.119"},{"issue":"15","key":"e_1_3_2_47_1","article-title":"STREAM: A randomized discontinuation, blinded, placebo-controlled phase II study of sorafenib (S) treatment of chemona\u00efve patients (pts) with metastatic uveal melanoma (MUM)","volume":"35","author":"Scheulen ME","year":"2017","unstructured":"Scheulen ME , KaempgenE, KeilholzUet al. STREAM: A randomized discontinuation, blinded, placebo-controlled phase II study of sorafenib (S) treatment of chemona\u00efve patients (pts) with metastatic uveal melanoma (MUM). J. Clin. Oncol.35(Suppl. 15), (2017).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0b013e328358b373"},{"issue":"15","key":"e_1_3_2_49_1","article-title":"Sunitinib versus dacarbazine as first-line treatment in patients with metastatic uveal melanoma","volume":"31","author":"Sacco JJ","year":"2013","unstructured":"Sacco JJ , NathanPD, DansonSet al. Sunitinib versus dacarbazine as first-line treatment in patients with metastatic uveal melanoma. J. Clin. Oncol.31(Suppl. 15), (2013).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2016.419"},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1223"},{"key":"e_1_3_2_52_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-008-9143-2"},{"key":"e_1_3_2_53_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-2243"},{"key":"e_1_3_2_54_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.2418"},{"key":"e_1_3_2_55_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-2925"},{"key":"e_1_3_2_56_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-3768.2008.01183.x"},{"key":"e_1_3_2_57_1","unstructured":"All-Ericsson C GirnitaL SeregardS BartolazziA JagerMJ LarssonO. Insulin-like Growth Factor-1 Receptor in Uveal Melanoma: A Predictor for Metastatic Disease and a Potential Therapeutic Target.4311\u20138 (2002)"},{"key":"e_1_3_2_58_1","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000234"},{"key":"e_1_3_2_59_1","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.12665"},{"key":"e_1_3_2_60_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-014-0066-9"},{"key":"e_1_3_2_61_1","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2008.273"},{"key":"e_1_3_2_62_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1410626111"},{"key":"e_1_3_2_63_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5623-3"},{"key":"e_1_3_2_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)80203-2"},{"key":"e_1_3_2_65_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1716"},{"key":"e_1_3_2_66_1","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000509"},{"key":"e_1_3_2_67_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-012-9862-2"},{"key":"e_1_3_2_68_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466"},{"key":"e_1_3_2_69_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1104621"},{"key":"e_1_3_2_70_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0118564"},{"issue":"15","key":"e_1_3_2_71_1","article-title":"Phase II study evaluating ipilimumab as a single agent in the first-line treatment of adult patients (Pts) with metastatic uveal melanoma (MUM): The GEM-1 trial","volume":"32","author":"Piulats Rodriguez JM","year":"2014","unstructured":"Piulats Rodriguez JM , Ochoade Olza M, CodesMet al. Phase II study evaluating ipilimumab as a single agent in the first-line treatment of adult patients (Pts) with metastatic uveal melanoma (MUM): The GEM-1 trial. J. Clin. Oncol.32(Suppl. 15), (2014).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_2_72_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-011-1089-0"},{"key":"e_1_3_2_73_1","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000175"},{"issue":"15","key":"e_1_3_2_74_1","article-title":"Efficacy and safety of nivolumab (NIVO) in patients with advanced melanoma (MEL) and poor prognostic factors who progressed on or after ipilimumab (IPI): results from a phase II study (CheckMate 172)","volume":"35","author":"Schadendorf D","year":"2017","unstructured":"Schadendorf D , AsciertoPA, HaanenJBAGet al. Efficacy and safety of nivolumab (NIVO) in patients with advanced melanoma (MEL) and poor prognostic factors who progressed on or after ipilimumab (IPI): results from a phase II study (CheckMate 172). J. Clin. Oncol.35(Suppl. 15), (2017).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_2_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2019.07.010"},{"key":"e_1_3_2_76_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2018.7070"},{"key":"e_1_3_2_77_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0459-y"},{"key":"e_1_3_2_78_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00550"},{"key":"e_1_3_2_79_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00605"},{"key":"e_1_3_2_80_1","volume-title":"Oral presentation at: 107th Annual Meeting of the American Association for Cancer Research (AACR).","author":"Zakharia Y","year":"2017","unstructured":"Zakharia Y . Interim analysis of the phase 2 clinical trial of the IDO pathway inhibitor indoximod in combination with pembrolizumab for patients with advanced melanoma. In: Oral presentation at: 107th Annual Meeting of the American Association for Cancer Research (AACR).Washington, DC (2017)."},{"key":"e_1_3_2_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2014.07.014"},{"key":"e_1_3_2_82_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.06.205"},{"key":"e_1_3_2_83_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1533209100"},{"key":"e_1_3_2_84_1","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-8-79"},{"issue":"1","key":"e_1_3_2_85_1","article-title":"Incomplete Freund's adjuvant reduces arginase and enhances Th1 dominance, TLR signaling and CD40 ligand expression in the vaccine site microenvironment","volume":"8","author":"Pollack KE","year":"2020","unstructured":"Pollack KE , MeneveauMO, MelssenMMet al. Incomplete Freund's adjuvant reduces arginase and enhances Th1 dominance, TLR signaling and CD40 ligand expression in the vaccine site microenvironment. J. Immunjournal. Cancer8(1), (2020).","journal-title":"J. Immunjournal. Cancer"},{"key":"e_1_3_2_86_1","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e31825481fe"},{"key":"e_1_3_2_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/0959-8049(92)90266-5"},{"key":"e_1_3_2_88_1","doi-asserted-by":"publisher","DOI":"10.1089\/jir.2010.0054"},{"key":"e_1_3_2_89_1","doi-asserted-by":"publisher","DOI":"10.1016\/0959-8049(96)00135-9"},{"key":"e_1_3_2_90_1","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0b013e3181d2ed67"},{"key":"e_1_3_2_91_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.5394"},{"key":"e_1_3_2_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30251-6"},{"issue":"5","key":"e_1_3_2_93_1","article-title":"Safety, pharmacokinetics and efficacy of IMCgp100, a first-in-class soluble TCR-antiCD3 bispecific t cell redirector with solid tumour activity: Results from the FIH study in melanoma","volume":"34","author":"Middleton MR","year":"2016","unstructured":"Middleton MR , StevenNM, EvansTJet al. Safety, pharmacokinetics and efficacy of IMCgp100, a first-in-class soluble TCR-antiCD3 bispecific t cell redirector with solid tumour activity: Results from the FIH study in melanoma. J. Clin. Oncol.34(Suppl. 5), (2016).","journal-title":"J. Clin. Oncol."},{"issue":"15","key":"e_1_3_2_94_1","article-title":"Redirected T cell lysis in patients with metastatic uveal melanoma with gp100-directed TCR IMCgp100: Overall survival findings","volume":"36","author":"Sato T","year":"2018","unstructured":"Sato T , NathanPD, Hernandez-AyaLet al. Redirected T cell lysis in patients with metastatic uveal melanoma with gp100-directed TCR IMCgp100: Overall survival findings. J. Clin. Oncol.36(Suppl. 15), (2018).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_2_95_1","volume-title":"ESMO Immuno-Oncology Virtual Congress.","author":"Sacco JJ","year":"2020","unstructured":"Sacco JJ , CarvajalR, ButlerMO. A phase (ph) II, multi-center study of the safety and efficacy of tebentafusp (tebe) (IMCgp100) in patients (pts) with metastatic uveal melanoma (mUM). In: ESMO Immuno-Oncology Virtual Congress. (2020)."},{"key":"e_1_3_2_96_1","volume-title":"AACR Annual Meeting 2021.","author":"Piperno-Neumann S","year":"2021","unstructured":"Piperno-Neumann S , HasselJC, RutkowskiP. Phase 3 randomized trial compared tebentafusp with investigator's choice in first line metastatic uveal melanoma. In: Presented at: AACR Annual Meeting 2021. (2021)."},{"key":"e_1_3_2_97_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2010.03.014"},{"key":"e_1_3_2_98_1","doi-asserted-by":"publisher","DOI":"10.1111\/ceo.12490"},{"key":"e_1_3_2_99_1","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.123.12.1639"},{"key":"e_1_3_2_100_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2016.07.012"},{"issue":"1","key":"e_1_3_2_101_1","first-page":"18","article-title":"Uveal melanoma","volume":"6","author":"Jager MJ","year":"2020","unstructured":"Jager MJ , ShieldsCL, CebullaCMet al. Uveal melanoma. Nat. Rev. Dis. Prim.6(1), 18\u201320 (2020).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"e_1_3_2_102_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28480"},{"key":"e_1_3_2_103_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40487-018-0056-8"},{"key":"e_1_3_2_104_1","doi-asserted-by":"publisher","DOI":"10.1002\/jso.23535"},{"key":"e_1_3_2_105_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00464-015-4527-9"},{"key":"e_1_3_2_106_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hpb.2019.11.002"},{"key":"e_1_3_2_107_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz176"},{"key":"e_1_3_2_108_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12010117"},{"key":"e_1_3_2_109_1","doi-asserted-by":"publisher","DOI":"10.1097\/00008390-200508000-00011"},{"key":"e_1_3_2_110_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-006-0155-z"},{"issue":"1","key":"e_1_3_2_111_1","first-page":"131","article-title":"Intra-arterial hepatic chemoebolization (TACE) of liver matastases from ocular melanoma with slow-release irinotecan-eluting beads. Early results of a phase II clinical study","volume":"23","author":"Fiorentini G","year":"2009","unstructured":"Fiorentini G , AlibertiC, del ConteAet al. Intra-arterial hepatic chemoebolization (TACE) of liver matastases from ocular melanoma with slow-release irinotecan-eluting beads. Early results of a phase II clinical study. In Vivo (Brooklyn).23(1), 131\u2013138 (2009).","journal-title":"In Vivo (Brooklyn)."},{"key":"e_1_3_2_112_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2009.03.064"},{"key":"e_1_3_2_113_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvir.2012.04.027"},{"key":"e_1_3_2_114_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.0705"},{"key":"e_1_3_2_115_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvir.2014.11.037"},{"key":"e_1_3_2_116_1","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2019190199"},{"issue":"4","key":"e_1_3_2_117_1","article-title":"A pilot study of intrahepatic yttrium-90 microsphere radioembolization in combination with intravenous cisplatin for uveal melanoma liver-only metastases","volume":"2","author":"Arulananda S","year":"2019","unstructured":"Arulananda S , ParakhS, PalmerJ, GoodwinM, AndrewsMC, CebonJ. A pilot study of intrahepatic yttrium-90 microsphere radioembolization in combination with intravenous cisplatin for uveal melanoma liver-only metastases. Cancer Rep.2(4), (2019).","journal-title":"Cancer Rep."},{"issue":"8","key":"e_1_3_2_118_1","first-page":"3062","article-title":"A phase I\u2013II study of isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to liver","volume":"6","author":"Alexander HR","year":"2000","unstructured":"Alexander HR , LibuttiSK, BartlettDL, PuhlmannM, FrakerDL, BachenheimerLC. A phase I\u2013II study of isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to liver. Clin. Cancer Res.6(8), 3062\u20133070 (2000).","journal-title":"Clin. Cancer Res."},{"issue":"17","key":"e_1_3_2_119_1","first-page":"6343","article-title":"Hyperthermic isolated hepatic perfusion using melphalan for patients with ocular melanoma metastatic to liver","volume":"9","author":"Alexander HR","year":"2003","unstructured":"Alexander HR , LibuttiSK, PingpankJFet al. Hyperthermic isolated hepatic perfusion using melphalan for patients with ocular melanoma metastatic to liver. Clin. Cancer Res.9(17), 6343\u20136349 (2003).","journal-title":"Clin. Cancer Res."},{"key":"e_1_3_2_120_1","doi-asserted-by":"publisher","DOI":"10.1097\/00008390-200402000-00011"},{"key":"e_1_3_2_121_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-008-9881-6"},{"key":"e_1_3_2_122_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2014.06.010"},{"key":"e_1_3_2_123_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.7.2589"},{"key":"e_1_3_2_124_1","doi-asserted-by":"publisher","DOI":"10.1007\/PL00012075"},{"key":"e_1_3_2_125_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6600521"},{"key":"e_1_3_2_126_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-015-4968-3"},{"key":"e_1_3_2_127_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.cmr.0000129377.22141.ea"},{"key":"e_1_3_2_128_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.00.927"},{"key":"e_1_3_2_129_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt585"},{"key":"e_1_3_2_130_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-019-03860-z"},{"key":"e_1_3_2_131_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.10025"},{"key":"e_1_3_2_132_1","doi-asserted-by":"publisher","DOI":"10.2217\/mmt-2019-0006"},{"key":"e_1_3_2_133_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00270-015-1276-z"},{"key":"e_1_3_2_134_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40644-019-0218-4"},{"key":"e_1_3_2_135_1","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2018.107"},{"key":"e_1_3_2_136_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2019.01.009"},{"key":"e_1_3_2_137_1","doi-asserted-by":"publisher","DOI":"10.1177\/1758834018757175"},{"key":"e_1_3_2_138_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.3551"},{"key":"e_1_3_2_139_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature09504"},{"issue":"15","key":"e_1_3_2_140_1","article-title":"Phase ib\/2a study of PLX51107, a small molecule BET inhibitor, in subjects with advanced hematological malignancies and solid tumors","volume":"36","author":"Patnaik A","year":"2018","unstructured":"Patnaik A , CarvajalRD, KomatsubaraKMet al. Phase ib\/2a study of PLX51107, a small molecule BET inhibitor, in subjects with advanced hematological malignancies and solid tumors. J. Clin. Oncol.36(Suppl. 15), (2018).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_2_141_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-0578"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2021-0318","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:43:04Z","timestamp":1719124984000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2021-0318"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,25]]},"references-count":139,"journal-issue":{"issue":"33","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["10.2217\/fon-2021-0318"],"URL":"https:\/\/doi.org\/10.2217\/fon-2021-0318","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"type":"print","value":"1479-6694"},{"type":"electronic","value":"1744-8301"}],"subject":[],"published":{"date-parts":[[2021,8,25]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-03-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}